Share on LinkedInShare on LinkedIn

ARTICLE · 17 AUGUST 2017

BPCIA Questions Continue To Arise For Biosimilar Applicants

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

Intellectual Property partner Gregory B. Sephton, special counsel Christine Willgoos and associate John P. Dillon's article "BPCIA Questions Continue To Arise For Biosimilar Applicants"...

United StatesIntellectual Property

Intellectual Property partner Gregory B. Sephton, special counsel Christine Willgoos and associate John P. Dillon's article "BPCIA Questions Continue To Arise For Biosimilar Applicants" appeared in Law360 on July 24, 2017. The article examines the Supreme Court's decision in Sandoz Inc. v. Amgen Inc., the first case under the Biologics Price Competition and Innovation Act of 2009.

Read the full article here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from